|Videos|February 9, 2021

TAILORx Trial

Author(s)Cancer Network Staff

Episodes in this series

Anthony Lucci, MD

EP. 1 Case Overview: Early-Stage Breast Cancer During COVID-19

Anthony Lucci, MD

EP. 2 Management of Early-Stage Breast Cancer

Anthony Lucci, MD

EP. 3 Sequencing of Therapies for Early-Stage Breast Cancer

Anthony Lucci, MD

EP. 4 TAILORx Trial

Anthony Lucci, MD

EP. 5 Early-Stage Breast Cancer: Gene Expression Profiling

EP. 6 Impact of COVID-19: Management of Early-Stage Breast Cancer

EP. 6 Impact of COVID-19: Management of Early-Stage Breast Cancer

A review of the TAILORx trial using the Oncotype DX assay to inform decisions in the adjuvant setting for treatment of HR+, HER2- breast cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.

October 2nd, 2026

Giredestrant Combo Boosts PFS in Pretreated ER+ Advanced Breast Cancer

In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.

$Hypofractionated PMRT Shows Durable 10-Year Control in High-Risk Breast Cancer$

September 28th, 2026

Hypofractionated PMRT Shows Durable 10-Year Control in High-Risk Breast Cancer

10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.

Trending on CancerNetwork

Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma

How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

FDA OKs Pirtobrutinib in Frontline CLL/SLL

NDA Submission Begins for Zipalertinib Combo in First-Line EGFR+ NSCLC